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M A J O R A R T I C L E
Measles Vaccination in the Presence or Absence
of Maternal Measles Antibody: Impact
on Child Survival
Peter Aaby,1,2 Cesário L. Martins,1 May-Lill Garly,1 Andreas Andersen,1,2 Ane B. Fisker,1 Mogens H. Claesson,3
Henrik Ravn,2 Amabelia Rodrigues,1 Hilton C. Whittle,4 and Christine S. Benn1,2
1Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; 2Research Centre for Vitamins and Vaccines, Bandim Health Project, Statens Serum
Institut, Copenhagen, and 3Institute of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen,
Denmark; and 4London School of Hygiene and Tropical Medicine, United Kingdom
Background. Measles vaccine (MV) has a greater effect on child survival when administered in early infancy,
when maternal antibody may still be present.
Methods. To test whether MV has a greater effect on overall survival if given in the presence of maternal measles
antibody, we reanalyzed data from 2 previously published randomized trials of a 2-dose schedule with MV given at 4–6
months and at 9 months of age. In both trials antibody levels had been measured before early measles vaccination.
Results. In trial I (1993–1995), the mortality rate was 0.0 per 1000 person-years among children vaccinated with
MV in the presence of maternal antibody and 32.3 per 1000 person-years without maternal antibody (mortality rate
ratio [MRR], 0.0; 95% conﬁdence interval [CI], 0–.52). In trial II (2003–2007), the mortality rate was 4.2 per 1000 per-
son-years among children vaccinated in presence of maternal measles antibody and 14.5 per 1000 person-years without
measles antibody (MRR, 0.29; 95% CI, .09–.91). Possible confounding factors did not explain the difference. In a com-
bined analysis, children who had measles antibody detected when they received their ﬁrst dose of MV at 4–6 months of
age had lower mortality than children with no maternal antibody, the MRR being 0.22 (95% CI, .07–.64) between 4–6
months and 5 years.
Conclusions. Child mortality in low-income countries may be reduced by vaccinating against measles in the pres-
ence of maternal antibody, using a 2-dose schedule with the ﬁrst dose at 4–6 months (earlier than currently recom-
mended) and a booster dose at 9–12 months of age.
Clinical Trials Registration. NCT00168558.
Keywords. maternal measles antibodies; age of measles vaccination; nonspeciﬁc beneﬁcial effects of measles
vaccine; 2-dose measles vaccination.
The primary effect of measles vaccination on child sur-
vival is assumed to be induction of measles antibody
and cellular immunity to prevent measles infection
and related deaths. Hence, the effect on child survival
should be proportional to measles vaccine (MV) efﬁca-
cy [1]. Although measles vaccination in the presence of
maternal antibody may induce cellular immune re-
sponses to measles, the antibody response is not opti-
mal [2]. It is therefore considered better to provide
MVwhenmaternal antibody has waned at 12 months of
age or later [3]. To prevent outbreaks in high-incidence
areas, the World Health Organization (WHO) recom-
mends MV at 9 months of age in low-income coun-
tries [1]. When measles control improves, MV can be
delayed to 12 months of age to obtain greater anti-
body responses [4], as happened in Latin America in
1996 [3].
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This policy ignores that MV may have nonspeciﬁc beneﬁcial
effects on child survival [5–10].Many observational studies and
randomized trials have shown that MV reduces mortality from
nonmeasles infections; furthermore, MV reduces the risk of
hospital admission for lower respiratory infections [11, 12].
The nonspeciﬁc effects are strongest when children are vacci-
nated early [6–10, 13]. A recent randomized trial tested MV at
4.5 months of age in addition to the recommended vaccination
at 9 months of age [5]. Children receiving 2 doses of MV
(per-protocol analysis) had 30% (95% conﬁdence interval
[CI], 6%–48%) lower mortality between 4.5 and 36 months of
age compared with children who followed the normal schedule
and received 1 dose at age 9 months. The reduction was 26% (95%
CI, 0–45%) when measles cases were censored [5]. Hence, even
though many children may have maternal measles antibody at
4–5 months, early MV had a marked effect on survival.
We therefore tested the hypothesis that MV in the presence of
maternal measles antibody may enhance the beneﬁcial nonspe-
ciﬁc effect on child survival.
METHODS
We reanalyzed data from 2 trials conducted at Bandim Health
Project (www.bandim.org) in Guinea-Bissau. In both trials,
children were randomized to receive an extra dose of MV at
4–6 months of age in addition to MV at 9 months of age.
Trial I: Early 2-Dose MV and Vitamin A Trial, 1993–1995
In 1993–1995, we enrolled 300 children in the districts Belem
and Mindara. The trial examined a 2-dose MV schedule at 6
and 9 months of age compared with 1 dose at 9 months [14].
The control group received inactivated polio vaccine (IPV) at
enrollment. The children were also randomized to vitamin A
supplementation (VAS) or placebo at 6 and 9 months of age
to examine whether VAS enhanced the antibody response to
MV. Children with a history of prior measles infection were
excluded from the trial. All children had measles antibody
assessed at 6 and 18 months of age. In 2000, follow-up was con-
ducted to examine long-term effects of VAS on measles anti-
body level [15]. The present analysis of survival until 5 years
of age is based on the 2000 follow-up. Verbal autopsies were
not conducted.
Trial II: Early 2-Dose Trial, 2003–2007
In a recent trial [5], we enrolled children at 4.5 months of age at
least 4 weeks after the third dose of diphtheria-tetanus-pertussis
vaccine (DTP). Children were randomized to receive either
standard-dose Edmonston-Zagreb MV at 4.5 and 9 months of
age, or no vaccine at 4.5 months and Edmonston-Zagreb or
Schwarz MV at 9 months of age. Between March and October
2004, we measured prevaccination measles antibody in 450
children randomized to MV at 4.5 months; we also measured
the antibody levels of their mothers [16]. Antibody samples
were not collected from the control group. Children have now
been followed to 5 years of age.
Measles Antibody Assay
The antibody level was measured with the hemagglutination in-
hibition (HAI) test [11, 17].The HAI assay used a local standard
calibrated against WHO’s International Reference serum [17].
The HAI assay assesses protection to clinical infection as well
as the plaque neutralizing assay [18]. With a 1:2 starting dilu-
tion, the minimum detectable level of measles antibody was
31.2 mIU, and the sensitivity of the assay was 15.6 mIU.
Role of Early Life Exposure to Measles Infection
Children exposed to measles infection in the ﬁrst 6 months of
life may have increased child mortality [19, 20]. Hence, children
with particularly high prevaccination antibody may have had
subclinical measles infection and be at higher risk of dying.
This would confound the assessment of possible beneﬁcial ef-
fect of receiving MV in presence of maternal antibody. There
is no way of knowing whether prevaccination antibody is mater-
nal or due to measles infection, except that maternal antibody
will be in the lower range and antibody due to exposure will be
in the higher range. In trial II we also tested the measles anti-
body of 431 mothers of the 450 children. Children with the
same or higher level than their mother at 4–5 months of age
would have had clinical or subclinical measles infection. In a
subgroup analysis, such children were excluded.
Statistical Analyses
Using Cox proportional hazards models with age as underlying
time, we compared mortality rates of different subgroups provid-
ing mortality rate ratios (MRRs) to assess the importance of ma-
ternal antibody at time of measles vaccination; differences
between groups were signiﬁcant at the 5% level if the CI excluded
1.0. In trial I, we compared subsequent mortality of early mea-
sles-vaccinated children with and without maternal measles anti-
body at enrollment and in parallel the mortality of control
children with and without measles antibody. One group had
no death and we therefore used the log-rank test, and the proﬁle
likelihood method for calculating an upper conﬁdence limit for
the MRR. In trial II we compared (1) mortality of early MV re-
cipients with and without maternal measles antibody and (2)
mortality of early MV recipients with and without maternal mea-
sles antibody with control children randomized to MV at 9
months of age. The proportional hazard assumption was assessed
graphically, and tested using Schoenfeld residuals (P = .71).
Ethical Approval
The protocols for the measles vaccine trials were approved by
the Danish Central Ethical Committee, the Gambia/MRC
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Scientiﬁc and Ethics committees, and the Guinean Ministry of
Health’s Research Coordination Committee.
RESULTS
Trial diagrams for trial I and trial II are shown in Supplemen-
tary Figure 1.
Trial I: Early 2-Dose MV and Vitamin A Trial, 1993–1995
Twenty-seven of 150 (18%) children who received MV at 6
months had detectable measles antibody (Table 1). Between 6
months and 5 years of age, 16 children died. All had undetect-
able measles antibody levels at 6 months of age; 13 died after the
second dose of MV at 9 months of age and before 5 years of age.
Among early MV recipients, vaccination in the presence of
measles antibody vs vaccination in the absence of measles
antibody was associated with signiﬁcant survival beneﬁts
(MRR, 0 [95% CI, 0–.52]; P = .048, log-rank test; Table 2). No
child died of measles infection. The effect was similar for chil-
dren receiving VAS or placebo with MV (data not shown). In
contrast, among IPV recipients, vaccination in presence of mea-
sles antibody was not associated with beneﬁts (MRR, 1.74 [95%
CI, .57–5.34]).
Trial II: Early 2-Dose Trial, 2003–2007
Among 450 children given MV at 4.5 months of age, 249 (55%)
had measles antibody (Table 1). Controlled for age, children
with measles antibody at measles vaccination had signiﬁcantly
lower mortality until 5 years of age than children without mea-
surable measles antibody; the MRR was 0.29 (95% CI, .09–.91;
Figure 1). Nearly all deaths (14/15) occurred after the second
dose of MV at 9 months (Figure 1). No death was due to measles
(Supplementary Table 1).
Some antibody could be due to measles, as there had been a
recent epidemic [16]. We therefore conducted an analysis exclud-
ing 16 children (1 death) who at 4.5 months had similar or higher
titers than their mothers. The result was the same among the re-
maining 434 children; children with measles antibody at measles
vaccination had an MRR of 0.23 (95% CI, .06–.82) compared
with children without detectable measles antibody.
Confounding factors, including sex, age of mother, weight-
for-age, season, infections, breastfeeding, twinning, high-risk
children (twins, motherless, low birth weight and nonbreast-
feeding) and decline in titers from mother to child, could not
explain why presence of maternal measles antibody had a ben-
eﬁcial effect; the adjusted MRRs varied between 0.22 and 0.33
(Table 3). Maternal HIV infection is associated with reduced
levels of measles antibody in the child. In the early 1990s, the
level of human immunodeﬁciency virus type 1 (HIV-1) infec-
tion [21] was very low in Bissau, so HIV-1 infection could
not explain higher mortality of children vaccinated in absence
of measles antibody in trial I. The expected HIV-1 prevalence
among mothers was 4%–5% during trial II [22]. Normally all
children are breastfed at 4 months of age in Guinea-Bissau,
Table 1. Mortality Until 60 Months of Age in Relation to the
Presence of Maternal Measles Antibody at the Time of Measles
Vaccination
Measles Antibody
Concentration
in the Child,a mIU/mL
Trial I [14]
(N = 150)
Trial II [5]
(N = 450)
Death/All, No. Death/All, No.
No detectable antibody 16/123 (13%) 11/201 (5%)
Detectable antibody
31.25 0/85
62.50 1/44
125 0/7 1/46
250 0/5 1/32
500 0/6 0/15
1000 0/7 1/11
2000 0/1 0/7
4000 0/6
8000 0/1 0/2
16 000 0/1
All detectable antibody 0/27 (0%) 4/249 (2%)
a Only children randomized to early vaccination.
Table 2. Mortality Between 6 Months and 5 Years of Age According to Presence of Maternal Measles Antibodies at Time of
Randomization to Measles Vaccine or Inactivated Polio Vaccine at 6 Months of Age (Trial Ia)
Early Measles Vaccination Control Children (IPV Vaccinated)
Had Measles Antibody
≥31.25 mIU/mLb
No Detectable
Measles Antibodyb
MRR
(95% CI)
Had Measles
Antibody ≥31.25 mIU/mLb
No Detectable
Measles Antibodyb MRR (95% CI)
0 (0/121) [27] 32.3 (16/495) [123] 0 (0–.52) 44.6 (4/90) [23] 25.2 (13/515) [127] 1.74 (.57–5.34)
The effect of vaccination with measles vaccination or IPV for children with and without maternal antibodies tended to differ statistically (P = .057, exact Poisson
regression).
Abbreviations: CI, confidence interval; IPV, inactivated polio vaccine; MRR, mortality rate ratio.
a See [14] for information on the trial.
b Data are presented as mortality rate/1000 person-years (deaths/person-years) [No.].
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but during the trial period the nongovernmental organization
responsible for prevention of maternal HIV transmission rec-
ommended that HIV-infected mothers not breastfeed their chil-
dren. In trial II, 4% were not breastfed and these children
presumably had HIV-infected mothers or mothers who died.
Among these children, none of the early recipients died
(Table 3). Hence, the beneﬁcial effect of having maternal anti-
body is not due to HIV-infected children having lower levels
and higher mortality.
The 450 measles-vaccinated children were also compared with
948 children enrolled in the same period and randomized to no
vaccine at 4.5 months and MVat 9 months of age. Overall, early
MV at 4.5 months reduced mortality between 4.5 months and
5 years of age (Table 4). However, the beneﬁcial effect was
found only among children who had maternal measles antibody
at vaccination (MRR, 0.30 [95% CI, .11–.82]). Children receiving
MV at 4.5 months of age without detectable measles antibody
had the same mortality as controls who received MV at 9 months
of age (MRR, 1.01 [95% CI, .53–1.95]) (Figure 1).
Combined Analysis
The trials were similar in collecting prevaccination samples,
having a second MV around 9 months, and having follow-up
to 5 years of age. We therefore conducted a combined analysis
adjusted for trial; MV at 4–6 months of age in presence of mea-
sles antibody was associated with an MRR of 0.22 (95% CI,
.07–.64) compared with MV in presence of no measles anti-
body; the MRR was 0.14 (95% CI, .02–1.09) for girls and 0.26
(95% CI, .07–.91) for boys. After the second dose of MV at 9
months of age, the MRR was 0.24 (95% CI, .08–.73).
DISCUSSION
Childhood survival was better for children who received MV in
presence of maternal antibody than for those who had no de-
tectable maternal antibody, and better than for those who re-
ceived only a single MV at 9 months of age. Control for
confounding factors did not explain the ﬁnding. In trial I
[14], maternal measles antibody had no effect on survival
among IPV-vaccinated children.
Confounding Factors and Limitations
Undetectable measles antibody levels could be associated with
higher inherent mortality. However, control for potential deter-
minants of antibody levels made no difference to the estimated
beneﬁt of MV (Table 3). Importantly, controlling for breast-
feeding, which is a proxy for maternal HIV infection in this
study setting, did not explain the ﬁndings.
High maternal measles antibody levels might be a proxy for
generally high maternal antibody levels and protection against
other infections. However, in trial I, there was no indication that
control children with detectable levels had better survival. Fur-
thermore, if lower mortality was due to protection against other
infections, the difference should have occurred before maternal
antibody wanes. This was not the case; in both trials the bene-
ﬁcial effect was equally pronounced after the second MV after 9
months of age, when maternal antibody levels are very low.
Children having no detectable antibody at MV were not a
group with a particularly high mortality. In both trials, children
vaccinated early having no maternal measles antibody had a
mortality rate similar to controls, who received MV at 9 months
of age.
Some children with high prevaccination measles antibody
levels may have had antibody due to subclinical or clinical mea-
sles infection [16, 19, 20]. When we examined this by excluding
children with antibody levels equal to or greater than their
mother’s, the effect of MV remained unchanged.
The trials were not planned to examine the effect of MV in
the presence of measles antibody; for example, we did not col-
lect antibody samples at 4.5 months of age from controls in trial
II. Hence, uncontrolled confounding factors for high maternal
antibody level could have played a role. Still. both studies sup-
ported that vaccination in presence of measles antibody may ex-
plain why all epidemiological studies indicate that early MV has
a better effect on child survival.
Consistency With Previous Observations
We have previously examined whether vaccination in presence
of maternal measles antibody inﬂuenced subsequent survival in
trials of 1 dose of early MV. We found support for lower mor-
tality after MV in presence of maternal antibody in the ﬁrst trial
of Edmonston-Zagreb in Guinea-Bissau [23].However, this was
Figure 1. Cumulative mortality between 4.5 months and 5 years of age
in relation to age of measles vaccination (MV) and presence of maternal
antibody (trial II [5]). Children randomized to MV at 4.5 months received
also MV at 9 months of age. Controls received only MV at 9 months of
age. Abbreviations: Ab, antibody; MV, measles vaccination.
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Table 3. Mortality Rate Ratios Between 4.5 and 5 Years of Age for Children With Maternal Measles Antibody ComparedWith Children Without Detectable Maternal Antibody at the Time
of Measles Vaccination at 4.5 Months of Age; Controlled for Potential Confounders in Stratiﬁed Analyses (Trial IIa)
Potential Confounding
Factor (Definition of
Stratum)
Mortality (Deaths/No.),
First Strata
Mortality (Deaths/No.),
Second Strata
MRR (95% CI)
RR of Having Undetectable Maternal Measles Antibody
Levels in the T2 Strata and Comment About Possible
Confounding
Undetectable
Antibody
Had Measles
Antibody
Undetectable
Antibody
Had Measles
Antibody
Unadjusted estimate 0.29 (.09–.91)
Maternal ageb (1: 14–24 y;
2: ≥25 y)
4/112 2/122 7/89 2/124 0.27 (.09–.86) Young mothers may be more likely to have
undetectable levels (RR = 1.15 [95% CI, .93–1.41])
and their children could have higher risk of dying.MRR = 0.45 (.08–2.47) MRR = 0.20 (.04–.94)
Sex (1: male; 2: female) 6/104 3/132 5/97 1/117 0.29 (.09–.90) There was no difference in risk of undetectable levels
for girls and boys (RR = 0.97 [95% CI, .79–1.19]).MRR = 0.38 (.10–1.53) MRR= 0.17 (.02–1.42)
Weight-for-age z scoreb (1:
z score <0; 2: z score ≥0)
6/111 4/142 5/90 0/107 0.27 (.09–.58) Maternal antibody concentration was not associated
with low weight for age (RR = 0.96 [95% CI, .78–
1.19]).MRR = 0.52 (.15–1.83) MRR = 0.00
Season (1: dry; 2: rainy) 5/76 1/127 6/125 3/122 0.29 (.09–.92) Maternal antibody levels measured in the rainy season
were more likely to be undetectable (RR = 1.35 [95%
CI, 1.09–1.68]) and mortality could be higher in the
rainy season.
MRR = 0.12 (.01–1.04) MRR= 0.50 (.12–1.99)
Breastfeeding at enrollment
(1: yes; 2: no)
11/192 4/243 0/9 0/6 0.28 (.09–.89) Not breastfeeding children, presumably due to the
mother being HIV infected, may be more likely to
have undetectable levels (RR = 1.36 [95% CI, .89–
2.08]); children born to HIV-infected mothers could
have higher mortality.
MRR = 0.28 (.09–.89) MRR=ND
Birth weight (1: normal; 2:
low)
10/184 3/235 1/17 1/14 0.30 (.09–.93) Low-birth-weight children are likely to have lower
maternal antibody (RR = 1.25 [95% CI, .89–1.75]) and
to have higher child mortality.MRR = 0.24 (.07–.86) MRR= 1.14 (.07–18.3)
Singletons (1: yes; 2: twins) 11/191 4/242 0/10 0/7 0.28 (.09–.89) Twins are likely to have lower maternal antibody
(RR = 1.33 [95% CI, .88–2.01]) and to have higher
child mortality.
MRR = 0.28 (.09–.89) MRR=ND
High-risk children (1: no; 2:
yes)
10/172 3/224 1/29 1/25 0.29 (.09–.91) High-risk children (twins, motherless children,
nonbreastfeeding, low birth weight) could have lower
maternal antibody levels (RR = 1.24 [95% CI, .94–
1.62]) and higher child mortality
MRR = 0.23 (.06–.84) MRR= 1.10 (.07–17.5)
Had fever or diarrhea at
enrollment (1: yes; 2: no)
1/21 1/14 10/180 3/235 0.30 (.09–.94) Children who are acutely sick have lower antibody levels
(RR = 1.38 [95% CI, 1.03–1.85]) and could have
higher subsequent child mortality.MRR = 1.62 (.10–26.0) MRR = 0.22 (.06–.82)
Decline in titers from
mother to childb,c (1: 0–4-
fold; 2: ≥5-fold)
3/63 2/137 8/133 2/98 0.29 (.09–.95) Children with the most marked decline in antibody level
are likely to have lower levels (RR = 1.83 [95% CI,
1.45–2.31]) and could have higher mortality.
MRR = 0.30 (.05–1.82) MRR= 0.33 (.07–1.58)
488
•
C
ID
2014:59
(15
A
u
gu
st)
•
A
aby
et
al
 at Library on September 10, 2014 http://cid.oxfordjournals.org/ Downloaded from 
not the case in the high-titer measles vaccine trial in Senegal
[24]. in which the children received DTP-IPV at the same
time as MV [25]. We have subsequently shown that DTP ad-
ministered with MV or after MV reduces the beneﬁt of MV
[25, 26]; this could potentially explain the Senegal ﬁnding.
Interpretation
The biological mechanisms explaining the beneﬁcial effect of
vaccination in presence of measles antibody are unknown. Sev-
eral not mutually exclusive mechanisms could be important.
First, it has been suggested from an early 2-dose study in
Sudan that early MV in presence of maternal antibody may
prime for a balanced humoral and cellular immune response
to subsequent revaccination [27].Animal studies have suggested
that maternal antibody not only confers passive immunity, but
also leaves a long-lasting imprint on the immune system of the
offspring [28], and that presence of maternal antibody at prima-
ry infection is required to ensure long-term protection [29]. Sec-
ond, maternal antibodies have undergone immune maturation
due to somatic hypermutation and gene conversion and are
thus guided toward the dominant epitopes on the measles
virus. In the presence of such high-afﬁnity maternal antibody,
the vaccinated child may respond to the variety of subdominant
epitopes, leading to more diverse T- and B-cell repertoires and
increased heterologous protection against other pathogens [30–
32]. Third, maternal antibody–antigen complexes are powerful
immunogens that are readily internalized and processed by an-
tigen-presenting cells, and this could result in enhanced T-cell
responses in infants immunized in presence of maternal anti-
body [32]. Last, recent studies have shown that BCG induces epi-
genetic changes that reprogrammonocytes to enhanced response
to unrelated infections [33]. Something similar could presumably
happen with MV in presence of maternal antibody [34].
Our results do not mean that nonspeciﬁc beneﬁcial effects
only occur when the initial MV is provided in the presence of
maternal measles antibody. In our studies, early MV was com-
pared with MV at 9 months of age, not with being measles un-
vaccinated. MV administered later after waning of maternal
antibody may also have nonspeciﬁc beneﬁcial effects compared
with not being measles vaccinated; for example, when MV was
introduced after 12 months of age in a community randomized
study in Bangladesh, there were signiﬁcant reductions in mor-
tality that could not be explained by prevention of measles in-
fection [35, 36].
Implications
The current measles vaccination program assumes a better ef-
fect of MV when maternal antibody wanes. However, all evi-
dence suggests that early MV has a stronger beneﬁcial effect
on child survival than later MV [5–11, 13]. There has been con-
cern that early MV in presence of maternal antibody mightTa
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reduce the subsequent protection against measles infection. In
trial II, antibody levels were generally lower among early MV
recipients than among children vaccinated later [37]. However,
the children had very good clinical protection before 9 months
of age [38], and following 2 doses at 4.5 and 9 months of age,
nearly all children tested had detectable measles antibody at 24
months of age and 97% had protective antibody levels. These
children will be followed to assess whether a third dose should
be needed [37]. Also, it should be noted that there is no corre-
lation between humoral and cellular responses [39].
The effect of different MV strategies is usually only assessed
in terms of its impact on measles antibody levels. However, the
most important criterion should be the overall effect on child
survival [5–9]. Furthermore, the vaccine should induce sufﬁ-
cient cellular immunity to protect against measles death and
sufﬁcient protective antibody levels to maintain herd immunity
against measles. An additional early MV would fulﬁll these cri-
teria, enhancing survival by initiating the nonspeciﬁc beneﬁcial
effect earlier and by ensuring that more children have maternal
antibody at ﬁrst MV. Early MV has also been shown to reduce
measles deaths [38], and in combination with a second dose at 9
months of age it induces protective antibody levels [37]. Hence,
early MV in addition to MV at 9 months of age would be a good
way to reduce child mortality.
If conﬁrmed in other studies, we would need to understand the
biological mechanisms explaining how vaccination in presence of
maternal antibody enhances protection against unrelated infec-
tions. The lack of a mechanistic understanding has been used
to justify not taking the nonspeciﬁc effects into consideration
[40]. The results herein suggest that immune enhancement by
maternal antibody is an important part of the mechanism ex-
plaining the nonspeciﬁc beneﬁcial effects of MV for child surviv-
al. This area of immunology has not been explored before.
It would be important to know whether the effect is restricted
to children who have measles antibody after natural infection of
their mother, or is also found when the maternal measles anti-
body was generated by a previous MV. Because the effect was
equally beneﬁcial in the mid-2000s (trial II), when more moth-
ers would have been measles vaccinated, and in the early 1990s
(trial I), it seems likely that the effect may also be produced by
vaccine-induced maternal antibody. Hence, it should be exam-
ined whether a beneﬁcial effect can be obtained by adding pas-
sive antibodies at time of measles vaccination to assure that all
children have the beneﬁt of MV in the presence of antibody.
Current MV policies may have to be reconsidered [41]. There
are several randomized trials from Africa which document that
MV provides protection against more than measles infection
[5, 8, 41, 42]. There is every reason to use the nonspeciﬁc bene-
ﬁcial effects to reduce child mortality in high-mortality coun-
tries. We may need to give the ﬁrst dose of MV earlier rather
than later, and any attempt to increase the age of MV may
lead to an increase in child mortality.
Table 4. Mortality Between 4.5 and 5 Years of Age in Relation to the Presence of Maternal Measles Antibody at the Time of
Randomization to Measles Vaccine (MV) or No MV at 4.5 Months of Age (Trial IIa)
Presence of Maternal Antibody, mIU/mL
Mortality Rate per 1000 Person-years
(Deaths/Person-years) [No.]
MRR (95% CI)Received MV at 4.5 mo
Controls (No MV at
4.5 mo)
All children 8.7 (15/1716) [450] 14.4 (50/3467) [948] 0.61 (.34–1.09)
No detectable antibody 14.5 (11/760) [201] 1.01 (.53–1.95)
Antibody: 31.25–16 000 4.18 (4/956) [249] 0.30 (.11–.82)
MRR (antibody/no detectable antibody) 0.29 (0.09–0.91)
Females 7.4 (6/814) [214] 17.9 (28/1562) [436] 0.42 (.17–1.01)
No detectable antibody 13.3 (5/376) [97]
Antibody: 31.25–16 000 2.3 (1/438) [117]
MRR (antibody/no detectable antibody) 0.17 (0.02–1.45)
Males 10.0 (9/901) [236] 11.6 (22/1905) [512] 0.87 (.40–1.89)
No detectable antibody 15.6 (6/383) [104]
Antibody: 31.25–16 000 5.8 (3/518) [132]
MRR (antibody/no detectable antibody) 0.38 (0.09–1.51)
The table includes children enrolled in the trial between March and October 2004—ie, the period in which prevaccination antibody samples were collected. All
children were offered the currently recommended MV at 9 months of age. All children have been followed to death, migration, or 5 years of age. Antibody level
at 4.5 months of age was only measured in children who received MV at 4.5 months of age and not in the controls who were to receive MV at 9 months of age.
Abbreviations: CI, confidence interval; MRR, mortality rate ratio; MV, measles vaccine.
a See [5] for information on the trial.
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